Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06173310 | RECRUITING | Borderline-resectable Pancreatic Cancer

DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer
Sponsor:

University of Alabama at Birmingham

Information provided by (Responsible Party):

Harrison Kim

Brief Summary:

The goal of this study is to test whether chemotherapy guided by a new imaging method named DCE-MRI can more effectively reduce a pancreatic tumor, enabling curable surgery, over the conventional method when a tumor is categorized as borderline resectable pancreatic cancer. UAB radiological research team has been studying a cutting-edge imaging technique named dynamic contrast-enhanced magnetic resonance imaging, or DCE-MRI, for over 10 years. This technique has been globally used to calculate the blood flow of various tissues, including tumors. Blood flow often serves as a critical indicator showing a disease status. For example, a pancreatic tumor typically has low blood flow, so it can be used as an indicator to identify the presence of a pancreatic tumor. In addition, an effective therapy can result in the increase of blood flow in a pancreatic tumor during the early period of treatment. Therefore, the investigators may be able to determine whether the undergoing therapy is effective or not by measuring the change of blood flow in the pancreatic tumor and deciding whether to continue the therapy or try a different one.

Condition or disease

Borderline-resectable Pancreatic Cancer

Intervention/treatment

Point-of-care Portable Perfusion Phantom (P4)

Phase

NA

Study Type : INTERVENTIONAL
Estimated Enrollment : 50 participants
Masking : NONE
Primary Purpose : DIAGNOSTIC
Official Title : DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer
Actual Study Start Date : 2024-10-10
Estimated Primary Completion Date : 2029-03
Estimated Study Completion Date : 2029-03

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 19 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Adult patients (age 19 years or older).
  • * Patients with newly diagnosed and untreated borderline resectable pancreatic cancer.
  • * Patients with signed informed consent.
Exclusion Criteria
  • * Any history of prior radiation or chemotherapy or surgical removal for pancreatic cancer.
  • * Participants with safety contraindications to MRI examination (determined by standard clinical screening).
  • * Participants who are pregnant, lactating or are planning to become pregnant during the study.
  • * Participants who are planning to father a child during the study.
DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

Location Details

NCT06173310

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Albama

University of Alabama at Birmingham

Birmingham, Albama, United States, 35294

RECRUITING

United States, Indiana

Indiana University Medical Center

Indianapolis, Indiana, United States, 46202